appear lenticular with extensions into the urethra or anterior fibromuscular zone (2, 3) . On DW-MRI, prostate cancers are high in signal due to reduced diffusion, whereas on apparent diffusion coefficient (ADC) maps, they are low in signal intensity (2) . On MR spectroscopy, elevated choline levels and/or an elevated ratio of choline to citrate are indicators of prostate cancer (4) . On DCE-MRI, prostate cancer usually shows early, rapid enhancement and early washout (5) .
Clinical roles of prostate MRI MRI for local staging after a "positive" TRUS-guided biopsy
As an example, we will follow the typical course of a patient with a rising PSA but no definable lesion on their DRE. Such patients undergo 6-24 systematic core biopsies under transrectal ultrasound guidance (Fig. 2) . Patients with an abnormal DRE and/or rising serum PSA usually undergo transrectal ultrasonography (TRUS) guided prostate biopsy, the accepted "gold standard" for diagnosis. The main limitation of the TRUS-guided biopsy is that only a small percentage of the gland is sampled. The lateral PZ may be oversampled, while the midline, antero-lateral, and anterior aspects of the prostate and the CG may be undersampled. The size, location, and extent of the tumor can influence decision making and are generally unknown on the basis of the biopsy alone. Therefore, such patients can be evaluated with an ERC MRI to determine the size of the tumor. The size or location of the lesion seen on MRI can trigger an additional guided biopsy. For instance, if the initial biopsy suggests a "minimal cancer", but the MRI identifies a large mass, the patient may then be re-biopsied to obtain a more representative sample (Fig.  3) . Prostate cancer is a multifocal, and biologically and histologically heterogeneous disease, which can easily lead to sampling errors (6) . Staging by MRI involves visualizing the size and location of the tumor, and the status of the prostate capsule (Fig. 4) , seminal vesicles, bladder wall, and local lymph nodes ( Fig. 5) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . It should be noted, however, that MRI generally underestimates nodal involvement because it relies on nodal enlargement. The use of MRI for local staging after a "positive" TRUS-guided biopsy constitutes approximately 48% of the total referrals at our center.
MRI for screening before a TRUS-guided biopsy
A recent debate on the clinical application of prostate MRI centers on whether it can be used as a screening tool before systematic prostate biopsies in patients with an elevated PSA and an abnormal DRE (Fig. 2) . Shimizu et al. (22) have recently reported that MRI before a biopsy resulted in a higher rate of prostate cancer detection in 122 patients who underwent T2W MRI and DW-MRI with only a 4-channel external phased array coil. The investigators argue that the use sequences are alternatives that yield comparable image quality.
Anatomically, the prostate can be divided into the peripheral zone and central gland (including the transitional and central-periurethral zones). The normal PZ appears high in signal on T2W MRI, whereas a normal CG has a lower and more heterogeneous signal intensity. The CG is separated from the PZ by a pseudocapsule or surgical capsule. The true capsule, a hypointense rim surrounding the PZ, defines the limits of the prostate and is the site of extracapsular extension. The neurovascular bundles, critical for erectile function, are located at approximately 5 and 7 o'clock posterolateral to the true capsule. The seminal vesicles appear as hyperintense thin-walled cystic structures on T2W MRI, whereas the more medial paired vas deferens are thick-walled and hypointense and can mimic seminal vesicle invasion (Fig.  1) . Lymph nodes draining the prostate can be found in the obturator fossa and the peri-rectal space, and higher in the midline of the retroperitoneum.
Prostate cancers usually arise in the PZ and appear as round or ill-defined low-signal-intensity foci on T2W MR images. Detecting tumors in the CG is more complex because the CG becomes progressively larger and more heterogeneous with age; CG tumors are defined as homogenous, low-signal-intensity lesions with irregular margins and without a capsule. They often invade the pseudocapsule or of MRI data during biopsies (e.g., TRUS-MRI fusion for guidance) can potentially decrease the number of patients undergoing unnecessary prostate biopsies and increase the yield of those who do, but the cost-effectiveness of this approach has not been demonstrated (23) (Fig. 6 ). Some patients, recognizing the "blind" nature of routine biopsies, request ERC MRIs before their first biopsy. Referrals to MRI for pre-biopsy screening constitute approximately 17% of total referrals in our practice.
MRI as a roadmap after one or more "negative" TRUS-guided biopsies
Patients with negative biopsies return to the screening pool (Fig. 2) . If their PSA levels continue to rise after a negative biopsy, the next step in patient management becomes challenging, especially considering that up to 90% of patients have a negative result after an initial negative biopsy (24, 25) . One option for such cases is the saturation biopsy, which may include obtaining 100 or more cores; however, this procedure can result in complications such as urinary retention, hematuria and sepsis, and is costly due to multiple specimen processing and interpretation (26) . Another approach is to use MRI to localize suspicious areas for biopsy, especially if the lesion is in the anterior and CG lesions, the site of approximately 20%-30% of all prostate cancers (27, 28 ). An MRI scan at this point may direct the biopsy to an area that would not ordinarily be sampled (Fig. 7) . Recently, MRI in patients with persistently elevated PSA and one or more prior negative prostate biopsies was reported to increase tumor detection rate by 25%-45% on a per-patient basis (29) (30) (31) (32) . In addition to using MR images as a virtual guide for repeat biopsies, the biopsy procedure can be performed under real-time MRI guidance or potentially combined with real-time TRUS to guide repeat biopsies (33, 34) . MRI has been used as a problem-solving tool following "negative" and "inconclusive" biopsies in 17% of our prostate MRI referrals. 
MRI as a monitoring tool for active surveillance
Because prostate cancer exists as a spectrum of pathologies that range from indolent to highly aggressive, and patients with indolent cancers may not require radical prostatectomy or radiation therapy, AS is often suggested for patients with lowvolume and clinically low-risk disease (35) (36) (37) (38) . Multiparametric MRI, including T2W MRI, DW-MRI, MR spectroscopy, and DCE-MRI, can potentially help to correctly stratify such patients in the pretreatment phase because it may help predict patterns of tumor growth and thus identify the prognosis (39) (40) (41) (42) (43) (44) (45) (46) .
Studies have suggested that AS may be an alternative to radical therapies for carefully selected patients (47, 48) . AS is an emerging methodology that involves serial PSA measurements and annual biopsies, and it has not been standardized (49, 50) . A few largescale clinical studies have recently reported favorable outcomes using AS of prostate cancer (51, 52) . Lesions eligible for AS can be depicted by multiparametric MRI and tracked, allowing tumors that transform to a more aggressive phenotype to be identified (53, 54) (Figs. 8 and 9 ). The AS patient population constitutes 13.5% of prostate MRI referrals in our practice.
MRI as a monitoring tool for treatment follow-up
The treatment options for patients with prostate cancer include radical prostatectomy (RP), hormone therapy, radiation therapy (e.g. external beam radiation and brachytherapy) and focal therapy (radiofrequency ablation, cryotherapy, high-intensity focus ultrasound, and cyberknife). Selection of the optimal treatment method is based on clinical tumor stage, Gleason score, PSA level, and other factors such as patient age, condition and other comorbidities. Patients are followed by serum PSA and DRE after treatment for prostate cancer. MRI can play a role in detecting local recurrence when PSA begins to rise after anadir. For instance, biochemical relapse after RP can occur in 15%-30% of patients (55) (56) (57) (58) . Currently, clinical nomograms are used to predict the risk of biochemical recurrence; however, these nomograms have some limitations related to their variables, such as the low specificity of serum PSA and underestimated Gleason score at biopsy. MRI has been shown to improve the detection of local recurrence in patients with RP in a few studies (59) (60) . Although it is challenging to detect local recurrence on T2W MR images, the combined use of T2W MRI with DCE-MRI results in a higher yield in detecting local recurrence (61) (Fig. 10) .
External-beam radiation therapy (EBRT) is employed in approximately one-third of prostate cancer patients, and biochemical recurrence can occur in 20%-40% in the first five years (62) . Detecting recurrence after EBRT can be challenging because the PSA level may not be a reliable marker, and the DRE can be non-specific due to atrophic and fibrotic changes in the irradiated prostate gland. Multi-parametric MRI, specifically MR spectroscopy and DCE-MRI, can help identify recurrences with high accuracy in post-radiotherapy patients (63) (64) (65) (66) . Post-treatment follow-up comprises 4.5% of prostate MRI referrals. Similar comments apply to focal therapies such as focal cryotherapy and high-intensity focused ultrasound (Fig. 11) . Among the available imaging modalities, MRI currently provides the most valuable anatomic and functional information about the prostate gland. Although MRI yielded disappointing results when used in staging, its role has expanded with changes in how prostate cancer is perceived, treated and followed. MRI is currently mostly used for localization and local staging in prostate cancer patients who are surgery or radiation candidates. However, in addition to its traditional roles, MRI is being used as a monitoring tool in AS and in RP and post-radiation patients; it is also used to help diagnose patients with negative prior biopsies but rising PSA (Fig.  2) . Prostate MRI has come of age in the PSA era. 
